Parkinson's disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group: 4-Aminopyridine 10 mg (Dalfyra®, Arvand Pharmed) is prescribed at a dose of one tablet every 12 hours for 6 weeks. Each patient is provided with 84 tablets of Dalfy
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Diagnosis of idiopathic Parkinson’s disease confirmed by a Parkinson’s disease fellowship-trained neurologist History of experiencing episodes of freezing of gait, with a baseline FOG score = 10 Age between 40 and 80 years Stable treatment regimen with no medication changes during the past month Receiving a stable dose of levodopa for the past 4 weeks Providing written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: History of hypersensitivity to 4-aminopyridine. History of seizures for any reason. Presence of severe cognitive impairment (MMSE < 24). Presence of another comorbidity that can impair gait, such as stroke or osteoarthritis Occurrence of severe adverse effects requiring discontinuation of the medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of freezing of gait (FOG score) as measured by the FOG Questionnaire.(this variable reflects the intensity of FOG episodes and will be used to assess the effect of 4-aminopyridine compared to placebo). Timepoint: questionnaire completed before and after the 6-week treatment. Method of measurement: freezing of gait (FOG )Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFahimeh mohaghegh
Iran University of Medical Sciences
Outcome results
None listed